Cosciens Biopharma Inc (CSCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 1,888 | 1,879 | 1,483 | 2,749 | 1,387 |
| Cost of Goods | 1,095 | 1,196 | 862 | 1,775 | 1,018 |
| Gross Profit | 793 | 683 | 621 | 974 | 369 |
| Operating Expenses | 1,618 | 3,985 | 3,806 | 4,102 | 3,046 |
| Operating Income | -730 | -3,106 | -2,323 | -2,353 | -2,659 |
| Interest Expense | 46 | 33 | 43 | 23 | 69 |
| Other Income | 593 | -16 | 547 | -324 | 54 |
| Pre-tax Income | -183 | -3,155 | -1,819 | -2,700 | -2,674 |
| Income Tax | N/A | 11 | N/A | -1 | N/A |
| Net Income Continuous | -183 | -3,164 | -1,819 | -2,701 | -2,674 |
| Net Income Discontinuous | 10,940 | N/A | N/A | N/A | -981 |
| Net Income | $10,757 | $-2,183 | $-1,819 | $-2,701 | $-3,655 |
| EPS Basic Total Ops | 3.42 | -0.69 | -0.57 | -0.85 | -1.16 |
| EPS Basic Continuous Ops | -0.06 | -1.00 | -0.57 | -0.85 | -0.85 |
| EPS Basic Discontinuous Ops | 3.48 | N/A | N/A | N/A | -0.31 |
| EPS Diluted Total Ops | 2.90 | -0.69 | -0.57 | -0.85 | -1.16 |
| EPS Diluted Continuous Ops | -0.05 | -1.00 | -0.57 | -0.85 | -0.85 |
| EPS Diluted Discontinuous Ops | 2.95 | N/A | N/A | N/A | -0.31 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.69 | -0.57 | -0.85 | -1.16 |
| EBITDA(a) | $-389 | $-2,818 | $-2,034 | $-2,155 | $-2,359 |